Signalling Pathways 2014 will take place in Sitges near Barcelona, Spain.
Building on the success of the first edition in 2013, it is with pleasure that we present the second ESMO Symposium on Signalling Pathways in Cancer.
This new series of symposia, initiated by the ESMO Personalised Medicine Task Force, provides an educational, in-depth update to oncology professionals about latest scientific developments behind molecular pathways in cancer and a personalised approach to cancer treatment.
This year we will focus on the PI3K/AKT/mTOR pathway in cancer. The programme will cover preclinical and clinical issues relevant for targeting all axis of the PI3K/AKT/mTOR pathway. Starting from the principles of signal transduction and basic principles, discussions will evolve around rationale and strategies to inhibit the PI3K/AKT/mTOR pathway in cancer and interactions with other systems at the molecular level.
Updates will also be provided on drugs in development or already approved indications, on aspects important for the drugging of this pathway in a range of malignant diseases, mechanisms of primary and secondary resistance, a profile of side effects and an excellent overview of clinical trials that examine the emerging pathway inhibitors.
Symposium Co-Chairs
Fabrice André
Cristiana Sessa
Symposium Officers
- Fabrice André, Villejuif, France, Co-Chair
- Cristiana Sessa, Bellinzona, Switzerland, Co-Chair
- Andrea Alimonti, Bellinzona, Switzerland
- Monica Arnedos, Villejuif, France
- Fortunato Ciardiello, Naples, Italy
- Johann de Bono, Sutton, UK
- Bryan Hennessy, Dublin, Ireland
- Josep Tabernero, Barcelona, Spain